食管癌患者腔内碘-125近距离放疗及3/4吞咽困难评分的可行性研究

IF 1.1 4区 医学 Q4 ONCOLOGY
Kaihao Xu, Chuan Tian, Yahua Li, Yiming Liu, Jianzhuang Ren, Xinwei Han, Dechao Jiao
{"title":"食管癌患者腔内碘-125近距离放疗及3/4吞咽困难评分的可行性研究","authors":"Kaihao Xu,&nbsp;Chuan Tian,&nbsp;Yahua Li,&nbsp;Yiming Liu,&nbsp;Jianzhuang Ren,&nbsp;Xinwei Han,&nbsp;Dechao Jiao","doi":"10.5114/jcb.2023.127857","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical results of nasal feeding nutritional tube (NFNT)-loaded iodine-125 (<sup>125</sup>I) seeds in intra-luminal brachytherapy (ILBT) for esophageal carcinoma (EC) patients with a 3/4 dysphagia score.</p><p><strong>Material and methods: </strong>From January 2019 to January 2020, 26 patients (female/male: 17/9, mean age: 75.3 years, dysphagia score 3/4: 6/20, mean Karnofsky score: 58.4) with EC underwent NFNT-loaded <sup>125</sup>I seed placement for both nutrition and brachytherapy. Technical and clinical success, D<sub>90</sub> (radiation dose received by 90% of tumor volume) and organ at risk (OAR) dose, complications, dysphagia-free time (DFT), and overall survival (OS) time were documented. Local tumor diameter, Karnofsky score, dysphagia score, and quality of life (QoL) were compared before and 6 weeks after tube placement.</p><p><strong>Results: </strong>Technical and clinical success rates were 100% and 76.9%, respectively. The D<sub>90</sub> and OAR doses were 39.7 Gy and 2.3 Gy, respectively. Eight cases (30.8%) experienced mild complications, but no seed loss, fistula, and massive bleeding were observed. Median DFT and OS were 3.1 months and 13.7 months, respectively. Tumor diameter and dysphagia score significantly decreased (<i>p</i> < 0.05), Karnofsky score significantly improved (<i>p</i> < 0.05), and QoL scores related to physical function, physical functioning, general health, vitality, and emotional functioning improved (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>NFNT-loaded <sup>125</sup>I brachytherapy for ILBT is technically a safe and effective strategy for EC patients with low Karnofsky scores, and can be a bridging therapy for advanced anti-cancer treatment.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/44/JCB-15-50789.PMC10324586.pdf","citationCount":"0","resultStr":"{\"title\":\"Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.\",\"authors\":\"Kaihao Xu,&nbsp;Chuan Tian,&nbsp;Yahua Li,&nbsp;Yiming Liu,&nbsp;Jianzhuang Ren,&nbsp;Xinwei Han,&nbsp;Dechao Jiao\",\"doi\":\"10.5114/jcb.2023.127857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the clinical results of nasal feeding nutritional tube (NFNT)-loaded iodine-125 (<sup>125</sup>I) seeds in intra-luminal brachytherapy (ILBT) for esophageal carcinoma (EC) patients with a 3/4 dysphagia score.</p><p><strong>Material and methods: </strong>From January 2019 to January 2020, 26 patients (female/male: 17/9, mean age: 75.3 years, dysphagia score 3/4: 6/20, mean Karnofsky score: 58.4) with EC underwent NFNT-loaded <sup>125</sup>I seed placement for both nutrition and brachytherapy. Technical and clinical success, D<sub>90</sub> (radiation dose received by 90% of tumor volume) and organ at risk (OAR) dose, complications, dysphagia-free time (DFT), and overall survival (OS) time were documented. Local tumor diameter, Karnofsky score, dysphagia score, and quality of life (QoL) were compared before and 6 weeks after tube placement.</p><p><strong>Results: </strong>Technical and clinical success rates were 100% and 76.9%, respectively. The D<sub>90</sub> and OAR doses were 39.7 Gy and 2.3 Gy, respectively. Eight cases (30.8%) experienced mild complications, but no seed loss, fistula, and massive bleeding were observed. Median DFT and OS were 3.1 months and 13.7 months, respectively. Tumor diameter and dysphagia score significantly decreased (<i>p</i> < 0.05), Karnofsky score significantly improved (<i>p</i> < 0.05), and QoL scores related to physical function, physical functioning, general health, vitality, and emotional functioning improved (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>NFNT-loaded <sup>125</sup>I brachytherapy for ILBT is technically a safe and effective strategy for EC patients with low Karnofsky scores, and can be a bridging therapy for advanced anti-cancer treatment.</p>\",\"PeriodicalId\":51305,\"journal\":{\"name\":\"Journal of Contemporary Brachytherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/44/JCB-15-50789.PMC10324586.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Contemporary Brachytherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5114/jcb.2023.127857\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/jcb.2023.127857","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价食管营养管(NFNT)载碘-125 (125I)粒子在食管腔内近距离放射治疗(ILBT)中治疗3/4吞咽困难患者的临床效果。材料与方法:2019年1月至2020年1月,26例EC患者(女/男:17/9,平均年龄:75.3岁,吞咽困难评分3/4:6/20,平均Karnofsky评分:58.4)接受了nnfnt负载125I种子放置,同时进行营养和近距离治疗。技术和临床成功,D90(接受肿瘤体积90%的辐射剂量)和器官危险(OAR)剂量,并发症,无吞咽困难时间(DFT)和总生存时间(OS)记录。比较置管前和置管后6周局部肿瘤直径、Karnofsky评分、吞咽困难评分和生活质量(QoL)。结果:技术成功率100%,临床成功率76.9%。D90和OAR剂量分别为39.7 Gy和2.3 Gy。8例(30.8%)出现轻度并发症,无种子丢失、瘘管、大出血。中位DFT和OS分别为3.1个月和13.7个月。肿瘤直径、吞咽困难评分显著降低(p < 0.05), Karnofsky评分显著提高(p < 0.05),躯体功能、躯体功能、总体健康、活力、情绪功能相关的生活质量评分显著提高(p < 0.05)。结论:nnfnt负载125I近距离治疗对于低Karnofsky评分的EC患者是一种安全有效的治疗策略,可作为晚期抗癌治疗的桥梁治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.

Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.

Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.

Intra-luminal iodine-125 brachytherapy in patients with esophageal carcinoma and 3/4 dysphagia score: A feasibility study.

Purpose: To evaluate the clinical results of nasal feeding nutritional tube (NFNT)-loaded iodine-125 (125I) seeds in intra-luminal brachytherapy (ILBT) for esophageal carcinoma (EC) patients with a 3/4 dysphagia score.

Material and methods: From January 2019 to January 2020, 26 patients (female/male: 17/9, mean age: 75.3 years, dysphagia score 3/4: 6/20, mean Karnofsky score: 58.4) with EC underwent NFNT-loaded 125I seed placement for both nutrition and brachytherapy. Technical and clinical success, D90 (radiation dose received by 90% of tumor volume) and organ at risk (OAR) dose, complications, dysphagia-free time (DFT), and overall survival (OS) time were documented. Local tumor diameter, Karnofsky score, dysphagia score, and quality of life (QoL) were compared before and 6 weeks after tube placement.

Results: Technical and clinical success rates were 100% and 76.9%, respectively. The D90 and OAR doses were 39.7 Gy and 2.3 Gy, respectively. Eight cases (30.8%) experienced mild complications, but no seed loss, fistula, and massive bleeding were observed. Median DFT and OS were 3.1 months and 13.7 months, respectively. Tumor diameter and dysphagia score significantly decreased (p < 0.05), Karnofsky score significantly improved (p < 0.05), and QoL scores related to physical function, physical functioning, general health, vitality, and emotional functioning improved (p < 0.05).

Conclusions: NFNT-loaded 125I brachytherapy for ILBT is technically a safe and effective strategy for EC patients with low Karnofsky scores, and can be a bridging therapy for advanced anti-cancer treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Contemporary Brachytherapy
Journal of Contemporary Brachytherapy ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
2.40
自引率
14.30%
发文量
54
审稿时长
16 weeks
期刊介绍: The “Journal of Contemporary Brachytherapy” is an international and multidisciplinary journal that will publish papers of original research as well as reviews of articles. Main subjects of the journal include: clinical brachytherapy, combined modality treatment, advances in radiobiology, hyperthermia and tumour biology, as well as physical aspects relevant to brachytherapy, particularly in the field of imaging, dosimetry and radiation therapy planning. Original contributions will include experimental studies of combined modality treatment, tumor sensitization and normal tissue protection, molecular radiation biology, and clinical investigations of cancer treatment in brachytherapy. Another field of interest will be the educational part of the journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信